VistaGen Therapeutics
VTGN
#9180
Rank
S$97.22 M
Marketcap
$3.49
Share price
2.80%
Change (1 day)
-50.46%
Change (1 year)

P/E ratio for VistaGen Therapeutics (VTGN)

P/E ratio as of December 2024 (TTM): -0.3985

According to VistaGen Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.398503. At the end of 2022 the company had a P/E ratio of -0.3209.

P/E ratio history for VistaGen Therapeutics from 2011 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-0.3209-94.67%
2021-6.02-19.26%
2020-7.46527.2%
2019-1.19-26.29%
2018-1.6199.21%
2017-0.81026.44%
2016-0.7612139.35%
2015-0.3180-70.97%
2014-1.10-44.84%
2013-1.99243.2%
2012-0.5786-87.66%
2011-4.69

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-3.82 858.86%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.